Literature DB >> 35230684

Assessment of Microsatellite Instability from Next-Generation Sequencing Data.

Victor Renault1, Emmanuel Tubacher1, Alexandre How-Kit2.   

Abstract

Microsatellite instability (MSI) is a genetic alteration due to a deficiency of the DNA mismatch repair system, where microsatellites accumulate insertions/deletions. This phenotype has been extensively characterized in colorectal cancer and is also sought in the context of Lynch syndrome diagnosis. It has recently been described in dozens of cancer types from whole genome/exome sequencing data, bearing some prognostic information. Moreover, MSI has also proven to be a major predicator of the response to immune checkpoint blockade therapy in solid cancer patients. Among the different methods developed for MSI detection in cancer, next-generation sequencing (NGS) is a promising and versatile technology offering many possibilities and advantages in diverse clinical applications compared to the gold standard PCR and capillary electrophoresis approach. NGS could notably increase the number of analyzed microsatellites and potentially be used to analyze other genetic alterations required for precision oncology. However, it requires the development of robust new computational algorithms for the analysis of NGS microsatellite data. In this chapter, we describe the different approaches developed for the assessment of MSI from NGS data in cancer, including the different microsatellite panels and computational algorithms proposed, highlighting their advantages and drawbacks, and their evaluation in different clinical applications.
© 2022. Springer Nature Switzerland AG.

Entities:  

Keywords:  Bioinformatics; Cancer; Computational methods; MSI detection method; Machine learning; Microsatellite instability; Next-generation sequencing

Mesh:

Year:  2022        PMID: 35230684     DOI: 10.1007/978-3-030-91836-1_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  80 in total

Review 1.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

2.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease.

Authors:  L A Aaltonen; R Salovaara; P Kristo; F Canzian; A Hemminki; P Peltomäki; R B Chadwick; H Kääriäinen; M Eskelinen; H Järvinen; J P Mecklin; A de la Chapelle
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

3.  Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.

Authors:  Sahra Bodo; Chrystelle Colas; Olivier Buhard; Ada Collura; Julie Tinat; Noémie Lavoine; Agathe Guilloux; Alexandra Chalastanis; Philippe Lafitte; Florence Coulet; Marie-Pierre Buisine; Denisa Ilencikova; Clara Ruiz-Ponte; Miriam Kinzel; Sophie Grandjouan; Hilde Brems; Sophie Lejeune; Hélène Blanché; Qing Wang; Olivier Caron; Odile Cabaret; Magali Svrcek; Dominique Vidaud; Béatrice Parfait; Alain Verloes; Ulrich J Knappe; Florent Soubrier; Isabelle Mortemousque; Alexander Leis; Jessie Auclair-Perrossier; Thierry Frébourg; Jean-François Fléjou; Natacha Entz-Werle; Julie Leclerc; David Malka; Odile Cohen-Haguenauer; Yael Goldberg; Anne-Marie Gerdes; Faten Fedhila; Michèle Mathieu-Dramard; Richard Hamelin; Badre Wafaa; Marion Gauthier-Villars; Franck Bourdeaut; Eamonn Sheridan; Hans Vasen; Laurence Brugières; Katharina Wimmer; Martine Muleris; Alex Duval
Journal:  Gastroenterology       Date:  2015-06-25       Impact factor: 22.682

4.  Microsatellite instability analysis: a multicenter study for reliability and quality control.

Authors:  T Bocker; J Diermann; W Friedl; J Gebert; E Holinski-Feder; J Karner-Hanusch; M von Knebel-Doeberitz; K Koelble; G Moeslein; H K Schackert; H C Wirtz; R Fishel; J Rüschoff
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

Review 5.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

6.  CAT25 is a mononucleotide marker to identify HNPCC patients.

Authors:  Francesca Bianchi; Eva Galizia; Romina Catalani; Laura Belvederesi; Concetta Ferretti; Fabio Corradini; Riccardo Cellerino
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

7.  Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Authors:  Wassim Abida; Michael L Cheng; Joshua Armenia; Sumit Middha; Karen A Autio; Hebert Alberto Vargas; Dana Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Emily Carbone; Ethan S Barnett; Melanie Hullings; Jaclyn F Hechtman; Ahmet Zehir; Jinru Shia; Philip Jonsson; Zsofia K Stadler; Preethi Srinivasan; Vincent P Laudone; Victor Reuter; Jedd D Wolchok; Nicholas D Socci; Barry S Taylor; Michael F Berger; Philip W Kantoff; Charles L Sawyers; Nikolaus Schultz; David B Solit; Anuradha Gopalan; Howard I Scher
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

8.  Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.

Authors:  Rebecca A Barnetson; Albert Tenesa; Susan M Farrington; Iain D Nicholl; Roseanne Cetnarskyj; Mary E Porteous; Harry Campbell; Malcolm G Dunlop
Journal:  N Engl J Med       Date:  2006-06-29       Impact factor: 91.245

Review 9.  Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer.

Authors:  Laura G Baudrin; Jean-François Deleuze; Alexandre How-Kit
Journal:  Front Oncol       Date:  2018-12-12       Impact factor: 6.244

Review 10.  Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Authors:  Michael M Boyiadzis; John M Kirkwood; John L Marshall; Colin C Pritchard; Nilofer S Azad; James L Gulley
Journal:  J Immunother Cancer       Date:  2018-05-14       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.